Julie Gerardi is the VP of Global Sales at SGI-DNA. Julie joined SGI-DNA in 2019 and is responsible for sales and business development strategy worldwide. She brings 25 years of expertise in developing go-to-market strategy for laboratory automation and a keen understanding of biological drug discovery workflows to the commercial leadership team.
Julie joined SGI-DNA from Definiens (AstraZeneca), where she held the position of Senior Director of Business Development in Strategic Markets, operationally in the Immuno-oncology arena. Prior to that she was the Drug Discovery Manager for Molecular Devices (Danaher). She has also been part of several successful start-ups including, Velocity11 which is now part of Agilent, and MWG Biotech, now a part of Eurofins.
Julie holds a B.S. Biotechnology Management/Biochemistry from Menlo College.